On the public citation graph
Prevention of COPD exacerbations: a European Respiratory Society/American Thoracic Society guideline
0 signed · 195 inferred · view as graph
Inferred edges come from two machine sources: sweeps of open repository metadata (mostly SSRN and Zenodo), and a bulk OpenAlex citation snapshot. Every row below is labelled with the one it came from. Neither is a complete citation index — absence here is not evidence of absence.
Is this your work? Sign in with ORCID and put your name on the
claims that are yours.
Reference health. See whether every reference in this work resolves to a
known work and none has been retracted — and get a dated CiteStamped
badge you can embed.
What this work says
Outgoing claims: the papers this work cites, builds on, or argues with.
inferredcites →https://doi.org/10.1016/j.pupt.2003.08.004openalex-snapshot
Effect of twelve-months therapy with oral ambroxol in preventing exacerbations in patients with COPD. Double-blind, randomized, multicenter, placebo-controlled study (the AMETHIST Trial)
inferredcites →https://doi.org/10.1016/j.rmed.2008.11.003openalex-snapshot
Fluticasone and N-acetylcysteine in primary care patients with COPD or chronic bronchitis
inferredcites →https://doi.org/10.1016/s0140-6736(05)66456-2openalex-snapshot
Effects of N-acetylcysteine on outcomes in chronic obstructive pulmonary disease (Bronchitis Randomized on NAC Cost-Utility Study, BRONCUS): a randomised placebo-controlled trial
inferredcites →https://doi.org/10.1016/s0140-6736(08)60869-7openalex-snapshot
Effect of carbocisteine on acute exacerbation of chronic obstructive pulmonary disease (PEACE Study): a randomised placebo-controlled study
inferredcites →https://doi.org/10.1016/s0140-6736(09)61255-1openalex-snapshot
Roflumilast in symptomatic chronic obstructive pulmonary disease: two randomised clinical trials
inferredcites →https://doi.org/10.1016/s0140-6736(14)62410-7openalex-snapshot
Effect of roflumilast on exacerbations in patients with severe chronic obstructive pulmonary disease uncontrolled by combination therapy (REACT): a multicentre randomised controlled trial
inferredcites →https://doi.org/10.1016/s2213-2600(13)70158-9openalex-snapshot
Once-daily indacaterol versus tiotropium for patients with severe chronic obstructive pulmonary disease (INVIGORATE): a randomised, blinded, parallel-group study
inferredcites →https://doi.org/10.1016/s2213-2600(13)70286-8openalex-snapshot
Twice daily N-acetylcysteine 600 mg for exacerbations of chronic obstructive pulmonary disease (PANTHEON): a randomised, double-blind placebo-controlled trial
inferredcites →https://doi.org/10.1016/s2213-2600(14)70019-0openalex-snapshot
Azithromycin maintenance treatment in patients with frequent exacerbations of chronic obstructive pulmonary disease (COLUMBUS): a randomised, double-blind, placebo-controlled trial
inferredcites →https://doi.org/10.1056/nejmc1306999openalex-snapshot
Cardiovascular Risks with Azithromycin
inferredcites →https://doi.org/10.1056/nejmoa040582openalex-snapshot
Oral Erythromycin and the Risk of Sudden Death from Cardiac Causes
inferredcites →https://doi.org/10.1056/nejmoa0909883openalex-snapshot
Susceptibility to Exacerbation in Chronic Obstructive Pulmonary Disease
inferredcites →https://doi.org/10.1056/nejmoa1008378openalex-snapshot
Tiotropium versus Salmeterol for the Prevention of Exacerbations of COPD
inferredcites →https://doi.org/10.1056/nejmoa1104623openalex-snapshot
Azithromycin for Prevention of Exacerbations of COPD
inferredcites →https://doi.org/10.1056/nejmp1302726openalex-snapshot
Cardiovascular Risks with Azithromycin and Other Antibacterial Drugs
inferredcites →https://doi.org/10.1136/bmj.39489.470347.adopenalex-snapshot
GRADE: an emerging consensus on rating quality of evidence and strength of recommendations
inferredcites →https://doi.org/10.1136/thx.2003.008730openalex-snapshot
Effect of exacerbations on quality of life in patients with chronic obstructive pulmonary disease: a 2 year follow up study
inferredcites →https://doi.org/10.1136/thx.2005.040527openalex-snapshot
Severe acute exacerbations and mortality in patients with chronic obstructive pulmonary disease
inferredcites →https://doi.org/10.1164/ajrccm.157.5.9709032openalex-snapshot
Effect of Exacerbation on Quality of Life in Patients with Chronic Obstructive Pulmonary Disease
inferredcites →https://doi.org/10.1164/rccm.200610-1563ocopenalex-snapshot
Effect of 1-Year Treatment with Roflumilast in Severe Chronic Obstructive Pulmonary Disease
inferredcites →https://doi.org/10.1164/rccm.200801-145ocopenalex-snapshot
Long-term Erythromycin Therapy Is Associated with Decreased Chronic Obstructive Pulmonary Disease Exacerbations
inferredcites →https://doi.org/10.1164/rccm.201402-0207ocopenalex-snapshot
Predictors of Chronic Obstructive Pulmonary Disease Exacerbation Reduction in Response to Daily Azithromycin Therapy
inferredcites →https://doi.org/10.1183/13993003.00214-2017openalex-snapshot
Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease 2017 Report: GOLD Executive Summary
inferredcites →https://doi.org/10.1183/13993003.00791-2016openalex-snapshot
Management of COPD exacerbations: a European Respiratory Society/American Thoracic Society guideline
inferredcites →https://doi.org/10.1183/16000617.00002215openalex-snapshot
Influence of N -acetylcysteine on chronic bronchitis or COPD exacerbations: a meta-analysis
inferredcites →https://doi.org/10.1186/1465-9921-11-10openalex-snapshot
Pulsed moxifloxacin for the prevention of exacerbations of chronic obstructive pulmonary disease: a randomized controlled trial
inferredcites →https://doi.org/10.1186/1465-9921-12-18openalex-snapshot
Reduction of exacerbations by the PDE4 inhibitor roflumilast - the importance of defining different subsets of patients with COPD
inferredcites →https://doi.org/10.1371/journal.pone.0159827openalex-snapshot
The Effectiveness and Safety of Fluoroquinolone-Containing Regimen as a First-Line Treatment for Drug-Sensitive Pulmonary Tuberculosis: A Systematic Review and Meta-Analysis
inferredcites →https://doi.org/10.1378/chest.12-2357openalex-snapshot
High-Dose N-Acetylcysteine in Stable COPD
inferredcites →https://doi.org/10.1378/chest.120.3.730openalex-snapshot
Erythromycin and Common Cold in COPD
What points at this work
Incoming claims: where this work appears in other papers’ reference lists and arguments.
inferred← citeshttps://doi.org/10.2139/ssrn.3863358openalex-extracted
A Benefit-Harm Analysis of Azithromycin for the Prevention of Acute Exacerbations of Chronic Obstructive Pulmonary Disease
inferred← citeshttps://doi.org/10.1002/14651858.cd001287.pub6openalex-snapshot
Mucolytic agents versus placebo for chronic bronchitis or chronic obstructive pulmonary disease
inferred← citeshttps://doi.org/10.1002/14651858.cd012930openalex-snapshot
Once daily long-acting beta2-agonists and long-acting muscarinic antagonists in a combined inhaler versus placebo for chronic obstructive pulmonary disease
inferred← citeshttps://doi.org/10.1002/14651858.cd012930.pub2openalex-snapshot
Once daily long-acting beta2-agonists and long-acting muscarinic antagonists in a combined inhaler versus placebo for chronic obstructive pulmonary disease
inferred← citeshttps://doi.org/10.1002/14651858.cd013024.pub2openalex-snapshot
Head-to-head oral prophylactic antibiotic therapy for chronic obstructive pulmonary disease
inferred← citeshttps://doi.org/10.1007/978-3-030-26710-0_22openalex-snapshot
Acute Exacerbation of COPD
inferred← citeshttps://doi.org/10.1007/978-3-030-43435-9_10openalex-snapshot
Medication Safety in Chronic Lung Disease with Cardiac Comorbidity
inferred← citeshttps://doi.org/10.1007/978-3-031-42859-3_6openalex-snapshot
Macrolide Use in Chronic Obstructive Pulmonary Disease
inferred← citeshttps://doi.org/10.1007/978-981-13-2598-4_6openalex-snapshot
Exacerbation of COPD by Air Pollution, Cold Temperatures, or Discontinuation of Medicine: What Should Be Measured to Help Prevent It?
inferred← citeshttps://doi.org/10.1007/s11739-024-03816-zopenalex-snapshot
Predicting COPD readmissions: a novel 2e index with traditional regression and machine-learning approaches
inferred← citeshttps://doi.org/10.1007/s12325-019-01128-9openalex-snapshot
Dyspnea in COPD: New Mechanistic Insights and Management Implications
inferred← citeshttps://doi.org/10.1007/s12325-020-01279-0openalex-snapshot
New Perspectives for Mucolytic, Anti-inflammatory and Adjunctive Therapy with 1,8-Cineole in COPD and Asthma: Review on the New Therapeutic Approach
inferred← citeshttps://doi.org/10.1007/s12325-020-01403-0openalex-snapshot
Profile of Cardiovascular Disease Patients Who are Diagnosed with COPD in a Smoking-Cessation Unit
inferred← citeshttps://doi.org/10.1007/s40265-026-02294-1openalex-snapshot
Mucus as a Treatable Trait in Chronic Airway Diseases
inferred← citeshttps://doi.org/10.1007/s40266-019-00680-xopenalex-snapshot
Optimizing Drug Therapies in Patients with COPD in the US Nursing Home Setting
inferred← citeshttps://doi.org/10.1016/j.amjmed.2018.05.003openalex-snapshot
Chronic Obstructive Pulmonary Disease Exacerbations: A Need for Action
inferred← citeshttps://doi.org/10.1016/j.amjmed.2022.06.001openalex-snapshot
COPD Readmission: The Missing Link
inferred← citeshttps://doi.org/10.1016/j.arbr.2019.10.012openalex-snapshot
Home hospitalization in pulmonology: Efficient management and high patient satisfaction
inferred← citeshttps://doi.org/10.1016/j.arbr.2020.08.006openalex-snapshot
Consensus document on the diagnosis and treatment of chronic bronchial infection in chronic obstructive pulmonary disease
inferred← citeshttps://doi.org/10.1016/j.arbr.2021.03.014openalex-snapshot
Spanish COPD guidelines (GesEPOC) 2021: Updated pharmacological treatment of stable COPD
inferred← citeshttps://doi.org/10.1016/j.arbr.2021.10.018openalex-snapshot
GesEPOC 2021 and GOLD 2021. Closer together or further apart?
inferred← citeshttps://doi.org/10.1016/j.arbres.2019.10.019openalex-snapshot
Hospitalización a domicilio en neumología: gestión eficiente con elevada satisfacción de los pacientes
inferred← citeshttps://doi.org/10.1016/j.arbres.2020.04.023openalex-snapshot
Documento de consenso sobre el diagnóstico y tratamiento de la infección bronquial crónica en la enfermedad pulmonar obstructiva crónica
inferred← citeshttps://doi.org/10.1016/j.arbres.2021.03.005openalex-snapshot
Actualización 2021 de la Guía Española de la EPOC (GesEPOC). Tratamiento farmacológico de la EPOC estable
inferred← citeshttps://doi.org/10.1016/j.arbres.2021.03.026openalex-snapshot
[Translated article] Spanish COPD guidelines (GesEPOC) 2021: Updated pharmacological treatment of stable COPD
inferred← citeshttps://doi.org/10.1016/j.arbres.2021.04.009openalex-snapshot
GesEPOC 2021 y GOLD 2021. ¿Más cerca o más lejos?
inferred← citeshttps://doi.org/10.1016/j.arbres.2021.04.030openalex-snapshot
[Translated article] GesEPOC 2021 and GOLD 2021. Closer together or further apart?
inferred← citeshttps://doi.org/10.1016/j.arbres.2025.10.008openalex-snapshot
Update 2025 of the Spanish COPD Guidelines (GesEPOC): Pharmacological Treatment of Stable COPD
inferred← citeshttps://doi.org/10.1016/j.arbres.2026.04.012openalex-snapshot
From Lungs to Vascular Health: Airflow Obstruction, Not Lung Function Decline, Predicts Atherosclerosis Progression Independent of Smoking Status
inferred← citeshttps://doi.org/10.1016/j.arbres.2026.06.019openalex-snapshot
Long-term Azithromycin Use in Severe COPD: Bridging the Gap Between Clinical Trials and Real-world Practice in the SPOCCAT Cohort
inferred← citeshttps://doi.org/10.1016/j.cger.2025.07.003openalex-snapshot
Chronic Obstructive Pulmonary Disease in the Older Adult
inferred← citeshttps://doi.org/10.1016/j.chest.2018.01.044openalex-snapshot
Clinical and Safety Outcomes of Long-Term Azithromycin Therapy in Severe COPD Beyond the First Year of Treatment
inferred← citeshttps://doi.org/10.1016/j.chest.2018.07.005openalex-snapshot
Pharmacological Therapy of COPD
inferred← citeshttps://doi.org/10.1016/j.chest.2021.05.024openalex-snapshot
Personalized Variable vs Fixed-Dose Systemic Corticosteroid Therapy in Hospitalized Patients With Acute Exacerbations of COPD
inferred← citeshttps://doi.org/10.1016/j.chest.2023.01.002openalex-snapshot
One Size Does Not Fit All
inferred← citeshttps://doi.org/10.1016/j.chest.2024.09.049openalex-snapshot
The Emerging Role of Alarmin-Targeting Biologics in the Treatment of Patients With COPD
inferred← citeshttps://doi.org/10.1016/j.crphar.2024.100195openalex-snapshot
The novel inhaled dual PDE3 and PDE4 inhibitor ensifentrine for the treatment of COPD: A systematic review and meta-analysis protocol on trough FEV1 and exacerbation according to PRISMA statement
inferred← citeshttps://doi.org/10.1016/j.jaci.2018.04.010openalex-snapshot
Blood eosinophil count thresholds and exacerbations in patients with chronic obstructive pulmonary disease
inferred← citeshttps://doi.org/10.1016/j.mcna.2020.02.003openalex-snapshot
Recent Advances in the Management of Acute Exacerbations of Chronic Obstructive Pulmonary Disease
inferred← citeshttps://doi.org/10.1016/j.resinv.2024.10.004openalex-snapshot
Efficacy and safety of mucolytics in patients with stable chronic obstructive pulmonary disease: A systematic review and meta-analysis
inferred← citeshttps://doi.org/10.1016/j.rmed.2020.106190openalex-snapshot
Use of mucolytics in COPD: A Delphi consensus study
inferred← citeshttps://doi.org/10.1016/j.rmed.2021.106526openalex-snapshot
Impact of COPD exacerbations leading to hospitalization on general and disease-specific quality of life
inferred← citeshttps://doi.org/10.1016/j.rmed.2025.108396openalex-snapshot
Anti-inflammatory agents for the management of COPD - Quo Vadis?
inferred← citeshttps://doi.org/10.1016/j.semerg.2019.03.009openalex-snapshot
El tratamiento broncodilatador en la prevención de las exacerbaciones de la EPOC
inferred← citeshttps://doi.org/10.1016/s2213-2600(21)00167-3openalex-snapshot
Safety and efficacy of itepekimab in patients with moderate-to-severe COPD: a genetic association study and randomised, double-blind, phase 2a trial
inferred← citeshttps://doi.org/10.1016/s2213-2600(24)00339-4openalex-snapshot
The global burden of COPD: epidemiology and effect of prevention strategies
inferred← citeshttps://doi.org/10.1016/s2213-2600(25)00404-7openalex-snapshot
Burden of chronic respiratory disease in Asia, 1990–2023: a systematic analysis for the Global Burden of Disease Study 2023
inferred← citeshttps://doi.org/10.1038/s41598-022-18326-1openalex-snapshot
Network pharmacology combined with pharmacodynamics revealed the anti-inflammatory mechanism of Tanreqing capsule against acute-exacerbation chronic obstructive pulmonary disease
inferred← citeshttps://doi.org/10.1038/s41598-025-14994-xopenalex-snapshot
Association between exacerbation history and airway bacterial community assessed by extended bacterial culture and sequencing approaches in stable COPD
inferred← citeshttps://doi.org/10.1055/a-2803-3367openalex-snapshot
The Impact of Acute Exacerbations of COPD on Patient Outcomes
inferred← citeshttps://doi.org/10.1055/a-2826-5752openalex-snapshot
Acute Exacerbation of Chronic Obstructive Pulmonary Disease: Pharmacological Treatment of AECOPD New Perspectives
inferred← citeshttps://doi.org/10.1055/a-2835-0340openalex-snapshot
Bidirectional Clinical Interactions among Exacerbations and Comorbidities in COPD: A Narrative Review
inferred← citeshttps://doi.org/10.1056/nejmra1900500openalex-snapshot
Update on Clinical Aspects of Chronic Obstructive Pulmonary Disease
inferred← citeshttps://doi.org/10.1080/09581596.2026.2692158openalex-snapshot
Prophylactic azithromycin for chronic obstructive pulmonary disease: a systematic review and meta-analysis of randomized clinical trials
inferred← citeshttps://doi.org/10.1080/13696998.2023.2182092openalex-snapshot
Incidence and medical costs of chronic obstructive respiratory disease in Spanish hospitals: a retrospective database analysis
inferred← citeshttps://doi.org/10.1080/14656566.2019.1570132openalex-snapshot
An evaluation of roflumilast and PDE4 inhibitors with a focus on the treatment of asthma
inferred← citeshttps://doi.org/10.1080/15412555.2019.1598965openalex-snapshot
Recovery Following Acute Exacerbations of Chronic Obstructive Pulmonary Disease – A Review
inferred← citeshttps://doi.org/10.1080/20018525.2026.2696116openalex-snapshot
Effect of evening vs. morning LAMA administration on risk of intensive care admission in COPD patients: influence of adherence post hoc analysis of the randomized controlled trial – LAMA BY NIGHT
inferred← citeshttps://doi.org/10.1080/25310429.2026.2742748openalex-snapshot
Monitoring symptoms and performance in rehabilitation: Can we detect COPD exacerbation?
inferred← citeshttps://doi.org/10.1093/jac/dky326openalex-snapshot
Effects of prophylactic antibiotics on patients with stable COPD: a systematic review and meta-analysis of randomized controlled trials
inferred← citeshttps://doi.org/10.1093/jac/dkz221openalex-snapshot
Improving antibacterial prescribing safety in the management of COPD exacerbations: systematic review of observational and clinical studies on potential drug interactions associated with frequently prescribed antibacterials among COPD patients
inferred← citeshttps://doi.org/10.1093/jvimsj/aalag220openalex-snapshot
Effect of low dose azithromycin on the fecal microbiome and fecal bile acids in healthy dogs
inferred← citeshttps://doi.org/10.1093/ndt/gfaf077openalex-snapshot
Chronic lung diseases and kidney disease: pathophysiology and management
inferred← citeshttps://doi.org/10.1093/qjmed/hcag217openalex-snapshot
Associations between glucagon-like peptide-1 receptor agonists and respiratory outcomes in chronic obstructive pulmonary disease and diabetes
inferred← citeshttps://doi.org/10.1097/cnq.0000000000000341openalex-snapshot
Acute Exacerbation of Chronic Obstructive Pulmonary Disease
inferred← citeshttps://doi.org/10.1097/eja.0000000000001067openalex-snapshot
The concept of peri-operative medicine to prevent major adverse events and improve outcome in surgical patients
inferred← citeshttps://doi.org/10.1097/mcp.0000000000000649openalex-snapshot
Asthma–COPD overlap: review of diagnosis and management
inferred← citeshttps://doi.org/10.1111/imj.15216openalex-snapshot
Patterns of azithromycin use in obstructive airway diseases: a real‐world observational study
inferred← citeshttps://doi.org/10.1136/bmjinnov-2024-001330openalex-snapshot
Innovative technologies for asthma and COPD management in the community: scanning the horizon using rapid systematic review methods
inferred← citeshttps://doi.org/10.1136/thorax-2022-219620openalex-snapshot
Budesonide/formoterol maintenance and reliever therapy versus fluticasone/salmeterol fixed-dose treatment in patients with COPD
inferred← citeshttps://doi.org/10.1136/thorax-2025-223095openalex-snapshot
Identifying azithromycin responders with an individual treatment effect model in COPD
inferred← citeshttps://doi.org/10.1136/thorax-2025-224164openalex-snapshot
Effect of maintenance macrolide de-escalation during the Australian summer on exacerbations of obstructive airway diseases: a randomised, double-blind, placebo-controlled trial
inferred← citeshttps://doi.org/10.1136/thoraxjnl-2017-211197openalex-snapshot
Home treatment of COPD exacerbation selected by DECAF score: a non-inferiority, randomised controlled trial and economic evaluation
inferred← citeshttps://doi.org/10.1136/thoraxjnl-2019-213929openalex-snapshot
British Thoracic Society guideline for the use of long-term macrolides in adults with respiratory disease
inferred← citeshttps://doi.org/10.1136/thoraxjnl-2019-214484openalex-snapshot
Acute exacerbations of chronic obstructive pulmonary disease: in search of diagnostic biomarkers and treatable traits
inferred← citeshttps://doi.org/10.1136/thoraxjnl-2021-217962openalex-snapshot
Benefit–harm analysis of azithromycin for the prevention of acute exacerbations of chronic obstructive pulmonary disease
inferred← citeshttps://doi.org/10.1164/rccm.201711-2239ocopenalex-snapshot
Exacerbations of Chronic Obstructive Pulmonary Disease and Cardiac Events. A Post Hoc Cohort Analysis from the SUMMIT Randomized Clinical Trial
inferred← citeshttps://doi.org/10.1164/rccm.201712-2493ocopenalex-snapshot
Determinants of Response to Roflumilast in Severe Chronic Obstructive Pulmonary Disease: Pooled Analysis of Two Randomized Trials
inferred← citeshttps://doi.org/10.1164/rccm.201801-0038ocopenalex-snapshot
Capturing Exacerbations of Chronic Obstructive Pulmonary Disease with EXACT. A Subanalysis of FLAME
inferred← citeshttps://doi.org/10.1164/rccm.201801-0113upopenalex-snapshot
Update in Chronic Obstructive Pulmonary Disease 2017
inferred← citeshttps://doi.org/10.1164/rccm.202002-0459edopenalex-snapshot
Guidance for the Better Care of Patients with Chronic Obstructive Pulmonary Disease
inferred← citeshttps://doi.org/10.1164/rccm.202212-2287ocopenalex-snapshot
A Double-Blind, Randomized, Placebo-controlled Trial of Long-Term Doxycycline Therapy on Exacerbation Rate in Patients with Stable Chronic Obstructive Pulmonary Disease
inferred← citeshttps://doi.org/10.1177/02692163221079697openalex-snapshot
Evidence-based management approaches for patients with severe chronic obstructive pulmonary disease (COPD): A practice review
inferred← citeshttps://doi.org/10.1177/0300060520946907openalex-snapshot
Romanian clinical guideline for diagnosis and treatment of COPD
inferred← citeshttps://doi.org/10.1177/1357633x20970402openalex-snapshot
Effects of post-discharge telemonitoring on 30-day chronic obstructive pulmonary disease readmissions and mortality
inferred← citeshttps://doi.org/10.1177/14799731221140797openalex-snapshot
Azithromycin use prior to ICU admission is associated with a lower short-term mortality for critically ill acute exacerbations of chronic obstructive pulmonary disease patients: A retrospective cohort study
inferred← citeshttps://doi.org/10.1183/13993003.00221-2018openalex-snapshot
New era for European Respiratory Society clinical practice guidelines: joining efficiency and high methodological standards
inferred← citeshttps://doi.org/10.1183/13993003.00328-2018openalex-snapshot
The overlap between bronchiectasis and chronic airway diseases: state of the art and future directions
inferred← citeshttps://doi.org/10.1183/13993003.00588-2019openalex-snapshot
Management of severe asthma: a European Respiratory Society/American Thoracic Society guideline
inferred← citeshttps://doi.org/10.1183/13993003.01003-2019openalex-snapshot
European Respiratory Society guidelines on long-term home non-invasive ventilation for management of COPD
inferred← citeshttps://doi.org/10.1183/13993003.01049-2024openalex-snapshot
Oral corticosteroids for cystic fibrosis pulmonary exacerbation: seeking the future in the past
inferred← citeshttps://doi.org/10.1183/13993003.01363-2019openalex-snapshot
Chronic respiratory symptoms but normal lung function: substantial disease burden but little evidence to inform practice
inferred← citeshttps://doi.org/10.1183/13993003.02006-2021openalex-snapshot
ERS statement: a core outcome set for clinical trials evaluating the management of COPD exacerbations
inferred← citeshttps://doi.org/10.1183/13993003.02042-2017openalex-snapshot
Genetic studies as a tool for identifying novel potential targets for treatment of COPD
inferred← citeshttps://doi.org/10.1183/16000617.0010-2018openalex-snapshot
Efficacy and safety profile of xanthines in COPD: a network meta-analysis
inferred← citeshttps://doi.org/10.1183/23120541.00136-2018openalex-snapshot
Circulating desmosine as a biomarker of azithromycin treatment response: apost hocanalysis of the COLUMBUS randomised controlled trial
inferred← citeshttps://doi.org/10.1183/23120541.00322-2019openalex-snapshot
Treatment of severe stable COPD: the multidimensional approach of treatable traits
inferred← citeshttps://doi.org/10.1183/23120541.00791-2023openalex-snapshot
Patients at risk of nontuberculous mycobacterial pulmonary disease who need testing evaluated using a modified Delphi process by European experts
inferred← citeshttps://doi.org/10.1183/2312508x.10006223openalex-snapshot
COPD as the new millennium began
inferred← citeshttps://doi.org/10.1183/2312508x.10016017openalex-snapshot
COPD and asthma overlap with bronchiectasis
inferred← citeshttps://doi.org/10.1183/2312508x.10032718openalex-snapshot
Treatment of lung disease in patients with AATD
inferred← citeshttps://doi.org/10.1186/s12879-020-05029-zopenalex-snapshot
Microbiology testing associated with antibiotic dispensing in older community-dwelling adults
inferred← citeshttps://doi.org/10.1186/s12890-025-03952-yopenalex-snapshot
Evening administration of long-acting muscarinic antagonists in COPD – a randomized controlled trial
inferred← citeshttps://doi.org/10.1186/s12890-026-04168-4openalex-snapshot
Impact of ambient particulate matter and meteorological factors on COPD risk and its association with blood eosinophilia
inferred← citeshttps://doi.org/10.1186/s12916-018-1104-9openalex-snapshot
Medications that reduce emergency hospital admissions: an overview of systematic reviews and prioritisation of treatments
inferred← citeshttps://doi.org/10.1186/s12931-018-0715-1openalex-snapshot
Chronic obstructive pulmonary disease guidelines in Europe: a look into the future
inferred← citeshttps://doi.org/10.1186/s12931-019-1017-yopenalex-snapshot
The pathology of small airways disease in COPD: historical aspects and future directions
inferred← citeshttps://doi.org/10.1186/s12931-020-01407-yopenalex-snapshot
Tiotropium in chronic obstructive pulmonary disease – a review of clinical development
inferred← citeshttps://doi.org/10.1186/s12931-020-01536-4openalex-snapshot
Decreased COPD prevalence in Sweden after decades of decrease in smoking
inferred← citeshttps://doi.org/10.1186/s12931-021-01776-yopenalex-snapshot
Real-world effectiveness of early intervention with fixed-dose tiotropium/olodaterol vs tiotropium in Japanese patients with COPD: a high-dimensional propensity score–matched cohort analysis
inferred← citeshttps://doi.org/10.1186/s12931-026-03802-3openalex-snapshot
Timely management of COPD exacerbations is associated with limited acute deterioration and early recovery: a prospective observational study
inferred← citeshttps://doi.org/10.1513/annalsats.201905-400ocopenalex-snapshot
High-Deductible Health Plans and Healthcare Access, Use, and Financial Strain in Those with Chronic Obstructive Pulmonary Disease
inferred← citeshttps://doi.org/10.1513/annalsats.202304-301ocopenalex-snapshot
A Cost-Effectiveness Analysis of Azithromycin for the Prevention of Acute Exacerbations of Chronic Obstructive Pulmonary Disease
inferred← citeshttps://doi.org/10.1513/annalsats.202308-673ocopenalex-snapshot
Adjunctive Systemic Corticosteroids for Pulmonary Exacerbations of Cystic Fibrosis
inferred← citeshttps://doi.org/10.1513/annalsats.202308-745edopenalex-snapshot
The Price Is Right: Cost-Effectiveness of Long-Term Azithromycin for Chronic Obstructive Pulmonary Disease
inferred← citeshttps://doi.org/10.18093/0869-0189-2021-31-3-272-295openalex-snapshot
Management of severe asthma: a European Respiratory Society/American Thoracic Society guideline
inferred← citeshttps://doi.org/10.21019/pharmacotherapyfirst.copd_overviewopenalex-snapshot
Chronic Obstructive Pulmonary Disease (COPD)
inferred← citeshttps://doi.org/10.2147/copd.s285385openalex-snapshot
Clinical Control Criteria to Determine Disease Control in Patients with Severe COPD: The CLAVE Study
inferred← citeshttps://doi.org/10.2147/copd.s298345openalex-snapshot
Towards Rational Prescription of Common Inhaler Medication in the Multimorbid COPD Patient
inferred← citeshttps://doi.org/10.2147/copd.s357491openalex-snapshot
The Impact of Chronic Bronchial Infection in COPD: A Proposal for Management
inferred← citeshttps://doi.org/10.2147/copd.s369804openalex-snapshot
The Effect of Maintenance Treatment with Erdosteine on Exacerbation Treatment and Health Status in Patients with COPD: A Post-Hoc Analysis of the RESTORE Dataset
inferred← citeshttps://doi.org/10.2147/copd.s478349openalex-snapshot
Triple Therapy with Budesonide/Glycopyrronium/Formoterol Fumarate Dihydrate versus Dual Therapies for Patients with COPD and Phenotypic Features of Asthma: A Pooled Post Hoc Analysis of KRONOS and ETHOS
inferred← citeshttps://doi.org/10.2147/copd.s561395openalex-snapshot
Mechanisms, Efficacy, Safety, and Pharmacoeconomics of Low-Dose, Long-Term Macrolide Antibiotics in the Treatment of Chronic Obstructive Pulmonary Disease: A Review
inferred← citeshttps://doi.org/10.2147/copd.s571480openalex-snapshot
A Proposed Checklist for Optimizing COPD Patient Discharge Processes in Italian Internal Medicine Wards
inferred← citeshttps://doi.org/10.2174/1573398x18666220903121800openalex-snapshot
Clinical Approaches to Minimize Readmissions of Patients with COPD: A Narrative Review
inferred← citeshttps://doi.org/10.2196/17863openalex-snapshot
Health-Related Effects of Home Nebulization With Glycopyrronium on Difficult-to-Treat Asthma: Post-Hoc Analyses of an Observational Study
inferred← citeshttps://doi.org/10.3389/fdgth.2025.1640585openalex-snapshot
Digital health technologies for improving the management of people with chronic obstructive pulmonary disease
inferred← citeshttps://doi.org/10.3389/fmed.2022.842948openalex-snapshot
The Influence of Prior Statin Use on the Prevalence and Exacerbation of Chronic Obstructive Pulmonary Disease in an Adult Population
inferred← citeshttps://doi.org/10.3389/fmed.2023.1174148openalex-snapshot
Management of acute COPD exacerbations in the internal medicine departments in Israel–a national survey
inferred← citeshttps://doi.org/10.3389/fmed.2025.1472947openalex-snapshot
Clinical efficacy of Bufei Yishen and Qutan Tongluo Cream on the treatment of patients with stable chronic obstructive pulmonary disease
inferred← citeshttps://doi.org/10.3389/fmed.2026.1810363openalex-snapshot
N-acetylcysteine: evidence based consensus document on the therapeutic advantages in respiratory diseases (NECTAR)
inferred← citeshttps://doi.org/10.3389/fpubh.2023.1112072openalex-snapshot
Patient experience with chronic obstructive pulmonary disease: a nationally representative demonstration study on quality and cost of healthcare services
inferred← citeshttps://doi.org/10.3390/biomedicines14040831openalex-snapshot
Airway Mucosal Defense: Mucins, Innate Immunity, and Contemporary Mucoactive Strategies
inferred← citeshttps://doi.org/10.3390/biomedicines9060675openalex-snapshot
Mucus, Microbiomes and Pulmonary Disease
inferred← citeshttps://doi.org/10.3390/ijms262311243openalex-snapshot
Precision Medicine Advances in Chronic Lung Diseases
inferred← citeshttps://doi.org/10.3390/jcm10061261openalex-snapshot
Management Challenges in Chronic Obstructive Pulmonary Disease in the COVID-19 Pandemic: Telehealth and Virtual Reality
inferred← citeshttps://doi.org/10.3390/jcm13061621openalex-snapshot
Implementation of the Care Bundle for the Management of Chronic Obstructive Pulmonary Disease with/without Heart Failure
inferred← citeshttps://doi.org/10.3390/jcm13144127openalex-snapshot
Anti-Inflammatory and Anti-Oxidant Properties of N-Acetylcysteine: A Fresh Perspective
inferred← citeshttps://doi.org/10.3390/jcm7110393openalex-snapshot
The Impact of Sepsis on the Outcomes of COPD Patients: A Population-Based Cohort Study
inferred← citeshttps://doi.org/10.3390/life14050542openalex-snapshot
Management of Refractory Chronic Obstructive Pulmonary Disease: A Review
inferred← citeshttps://doi.org/10.3390/medsci6020050openalex-snapshot
Is It Time to Change the Definition of Acute Exacerbation of Chronic Obstructive Pulmonary Disease? What Do We Need to Add?
inferred← citeshttps://doi.org/10.3390/ph16020192openalex-snapshot
Potential of Lactoferrin in the Treatment of Lung Diseases
inferred← citeshttps://doi.org/10.34142/hsr.2020.06.01.06openalex-snapshot
The dynamics of the functional state of the cardio-respiratory system of patients hospitalized with pneumonia, exacerbation of COPD, and bronchial asthma
inferred← citeshttps://doi.org/10.35366/nts191aopenalex-snapshot
Guía de Práctica Clínica Mexicana para el diagnóstico y tratamiento de la Enfermedad Pulmonar Obstructiva Crónica GUÍA MEXICANA DE EPOC, 2020
inferred← citeshttps://doi.org/10.4081/monaldi.2025.3531openalex-snapshot
Coexistence of upper airway obstruction on spirometry with flow volume loop in patients with chronic obstructive pulmonary disease
inferred← citeshttps://doi.org/10.4103/ijrc.ijrc_177_22openalex-snapshot
Managing Acute Exacerbation of Chronic Obstructive Pulmonary Disease: What\'s New?
inferred← citeshttps://doi.org/10.4103/jalh.jalh_38_25openalex-snapshot
Serum Magnesium Level and Acute Exacerbation in Chronic Obstructive Pulmonary Disease
inferred← citeshttps://doi.org/10.4187/respcare.06068openalex-snapshot
Clinical Pharmacology of Oral Maintenance Therapies for Obstructive Lung Diseases
inferred← citeshttps://doi.org/10.4236/ojrd.2025.153011openalex-snapshot
Therapeutic Role of Carbocysteine in Chronic Respiratory and Otorhinolaryngological Diseases: A Systematic Review and Meta-Analysis
inferred← citeshttps://doi.org/10.55783/amf.200702openalex-snapshot
Enfermedad pulmonar obstructiva crónica
inferred← citeshttps://doi.org/10.6084/m9.figshare.13161744openalex-snapshot
Additional file 5 of Decreased COPD prevalence in Sweden after decades of decrease in smoking
inferred← citeshttps://doi.org/10.6084/m9.figshare.13161750openalex-snapshot
Additional file 1 of Decreased COPD prevalence in Sweden after decades of decrease in smoking
inferred← citeshttps://doi.org/10.6084/m9.figshare.14803991openalex-snapshot
Additional file 1 of Real-world effectiveness of early intervention with fixed-dose tiotropium/olodaterol vs tiotropium in Japanese patients with COPD: a high-dimensional propensity score–matched cohort analysis
inferred← citeshttps://doi.org/10.7326/aitc202008040openalex-snapshot
Chronic Obstructive Pulmonary Disease
inferred← citeshttps://doi.org/10.7759/cureus.102479openalex-snapshot
Comparison of Diagnostic and Therapeutic Protocols for Chronic Obstructive Pulmonary Disease (COPD): Global Initiative for Chronic Obstructive Lung Disease (GOLD) vs. American Thoracic Society/European Respiratory Society (ATS/ERS) Guidelines
inferred← citeshttps://doi.org/10.7861/clinmed.2020-0359openalex-snapshot
Quality of smoking cessation advice in guidelines of tobacco-related diseases: An updated systematic review
inferred← citeshttps://doi.org/10.9778/cmajo.20200157openalex-snapshot
Long-term macrolide therapy for chronic obstructive pulmonary disease: a population-based time series analysis
Editorial review for independent work. ICSAC — the Institute for Complexity
Science and Advanced Computing — runs a structured editorial panel for researchers
publishing outside journals, and publishes on CiteStamp rails. Submission is free
and goes through ORCID: icsacinstitute.org/submit.